Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11064-11075
DOI: 10.1111/dom.71292 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.09.2026. Verfasst von Vivian Kliim-Hansen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark. Hauptthemen laut MEDLINE: Oxytocin, Blood Glucose, Bone Remodeling, Glucose. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Herlev and Gentofte Hospital, the Independent Research Fund Denmark, The Leona M. and Harry B. Helmsley Charitable Trust, Center for Clinical Metabolic Research, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen.
Abstract (Originalsprache)
Aim
Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and markers of bone turnover in healthy men. Materials and Methods In a randomised, placebo‐controlled, double‐blind, crossover study, healthy men received intravenous infusions of oxytocin (0.1 or 0.2 IU/min, or placebo [saline], respectively) on three separate days during a three‐hour intravenous graded glucose infusion with increases every 30 min (2–12 mg/kg/min). The primary outcome was baseline‐subtracted area under the curve for C‐peptide concentrations. Secondary outcomes included concentrations of plasma glucose, glucagon, glucose‐dependent insulinotropic polypeptide (GIP), glucagon‐like peptide 1 (GLP‐1), carboxy‐terminal collagen crosslink (CTX), procollagen Type 1 amino‐terminal propeptide (P1NP) and serum triglycerides.
Results
Twenty men (age: 24.9 ± 3.2 years; BMI: 23.8 ± 1.5 kg/m 2 ) were included. Peak plasma oxytocin concentrations: 193 ± 29 and 401 ± 66 pg/mL. Circulating concentrations of plasma glucose, C‐peptide, glucagon, GIP, GLP‐1, CTX, P1NP and triglyceride were similar across study visits. Neither oxytocin dose affected C‐peptide response or any secondary metabolic outcomes compared with placebo.
Conclusion
Acute intravenous oxytocin infusion resulting in supraphysiological plasma concentrations did not modulate pancreatic or gut hormone secretion, or markers of bone turnover during a controlled, stepwise glucose challenge in healthy men, suggesting limited acute metabolic and skeletal effects of oxytocin under these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark.
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Novo Nordisk A/S, Søborg, Denmark.
- Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
ORCID-Profile: Vivian Kliim-Hansen, Ida M Gether, Jens J Holst, Filip K Knop, Lærke S Gasbjerg
Förderung
- Herlev and Gentofte Hospital, the Independent Research Fund Denmark
- The Leona M. and Harry B. Helmsley Charitable Trust
- Center for Clinical Metabolic Research, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen
- Leona M. and Harry B. Helmsley Charitable Trust
Zitieren
APA
Kliim-Hansen, V., Gether, I. M., Thomas, A. M., Ellegaard, A. M., Pedersen, M. G., Holst, J. J., Hartmann, B., Knop, F. K., Gasbjerg, L. S., & Lund, A. B. (2026). Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men. Diabetes, Obesity and Metabolism, 28(12), 11064-11075. https://doi.org/10.1111/dom.71292
Vancouver
Kliim-Hansen V, Gether IM, Thomas AM, Ellegaard AM, Pedersen MG, Holst JJ, et al. Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men. Diabetes, Obesity and Metabolism. 2026;28(12):11064-11075. doi:10.1111/dom.71292
BibTeX
@article{KliimHansen2026,
author = {Kliim-Hansen, Vivian and Gether, Ida M and Thomas, Aliya M and Ellegaard, Anne-Marie and Pedersen, Miriam G and Holst, Jens J and Hartmann, Bolette and Knop, Filip K and Gasbjerg, Lærke S and Lund, Asger B},
title = {Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11064--11075},
doi = {10.1111/dom.71292}
}
EUVIMED